Sacra estimates that Noom hit $1B in ARR in 2023, growing 25% YoY with 1.5M subscribers paying anywhere from $17/month to $70/month depending on the length of their subscription renewal cycle, with revenue largely coming from Noom's core weight loss app (vs Noom Mood, its mental health app and Noom Med, its Ozempic D2C healthcare product). In February 2025, Noom disclosed that its GLP-1 Rx and pill-based generic medication programs together grew to a $100M revenue run-rate within four months of launching in September 2024.

Noom pivoted their $4M/year B2B business into a D2C weight loss app in 2017, growing from $12M ARR in 2017 to $600M ARR in 2021 with aggressive ad spend that grew from $5M to $330M.

Noom counter-positioned against WeightWatchers' (NYSE: WW) brand of in-person weight loss support groups (mainly for older women) as a mobile-native, science-backed app with fully-virtual text-based coaching, targeting ex-WeightWatchers users and capturing the upside of their decline (WeightWatchers revenue steadily declined from $1.83B in 2012 to $890M in 2023).

As of the end of 2023, Noom had roughly 1.5M paying subscribers paying anywhere from $17/month to $70/month depending on the length of their subscription renewal cycle for access to the paid features in the app—the coaching, community, and content. Noom disclosed in February 2025 that it has welcomed 8M+ women ages 40-60 into its program. Noom and WeightWatchers together account for roughly 60% of global weight loss app revenue.

Noom is valued at $3.66 billion as of their 2021 Series F. The company generated $600M in revenue in 2021, implying a revenue multiple of 6.17x.

The company has raised over $650 million in total funding across multiple rounds, with investments from prominent venture capital firms and strategic investors. Key investors include Silver Lake, Sequoia Capital, and Temasek Holdings. The most recent funding has included participation from Oak HC/FT Partners and Serena Ventures.

Noom's (2008) core product is a weight loss app that combines the food and activity tracking of apps like MyFitnessPal (2005) and LoseIt! (2008) with the human coaching and diet scoring of WeightWatchers (NASDAQ: WW), with colors (green, red, yellow) for different foods, rather than WeightWatchers's point-based system.

Noom currently offers the following products:

Noom's business model is primarily subscription-based, with users paying monthly or annual fees for access to the programs. The company has also diversified revenue streams through B2B partnerships and the addition of prescription medication services.

Noom is a subscription-based digital health platform that offers personalized weight loss and wellness programs. The company's core revenue stream comes from consumer subscriptions to its mobile app, which combines AI-powered content delivery with human coaching to drive behavior change.

Noom's B2C model hinges on a hybrid coaching approach that uses AI to enable their human "coaches" (who cost $19-24/hr) to manage 300-400 users each, contrasting sharply with competitors like Talkspace, which uses licensed therapists (costing ~$68/hr), or Vida Health and Omada, which employ registered dieticians and nutritionists (about ~$30/hr) managing only 7-15 users each.

Noom's pricing model is based on auto-renewing subscription plans of varying lengths, from monthly to annual. The monthly plan is priced at $70, while longer plans offer discounts, with the annual plan costing $209 (about $17.42 per month). This tiered pricing strategy incentivizes longer-term commitments, improving customer retention and lifetime value. Noom also offers a free tier to lower the barrier to entry and expand its funnel, as well as a 7-14 day trial period with various pricing options.

For its medication offerings, Noom has introduced multiple pricing tiers across different health categories. Its GLP-1 programs include a Microdose GLP-1Rx Program at $99 to start then $199/month (including medication if prescribed), smaller compounded doses of semaglutide starting at $149 for the first month (positioned well below the $349 price point for 2.5mg branded Wegovy/Zepbound vials), and Proactive Health Microdose GLP-1Rx at $149/month which includes at-home biomarker testing every four months. Noom + HRT Rx is priced at $69 to start then $89/month for cream, and $99 to start then $149/month for patch.

At its peak in early 2021, Noom employed around 2,700 coaches, representing the majority of its 3,000-person workforce, though this number decreased to 1,000 by October 2022 as the company increased its use of LLMs in the support flow.

Noom's B2B2C business hinges on selling Noom as a benefit into employers and health plans and into pharmaceutical companies (as the support arm of a drug protocol), with the value proposition of 1) reducing healthcare costs overall by solving obesity (21% of healthcare costs associated with being overweight), and 2) improving adherence with long-term drug treatments like GLP-1s.

Noom has built out significant enterprise distribution partnerships, including a collaboration with Highmark to offer Noom: Weight Management to nearly 2 million eligible members beginning in 2026. The partnership includes journeys for weight, diabetes prevention, and diabetes, with AI-powered tools like smart food logging and body scan and access to the GLP‑1 Companion. Noom also partnered with Castlight Health to distribute Noom programs (Noom Weight, Noom Med, Noom Diabetes, Noom Diabetes Prevention) to employers and health plans via Castlight's platform, with Castlight claiming its platform can drive a 3.25x increase in engagement.

Enterprise revenue today appears to be a fraction of Noom's D2C business, although ex-employee accounts suggest that Noom has approximately 250 active B2B partnerships as of 2024.

Noom competes in the digital health and weight loss market, facing competition from traditional weight loss programs, other digital health platforms, and emerging GLP-1 drug providers.

Noom's primary competition comes from established weight loss companies like WeightWatchers (WW) and Jenny Craig. These companies have pivoted to incorporate digital elements, but Noom differentiates itself through its psychology-based approach and mobile-first platform.

WW, for instance, has struggled to transition its in-person meeting model to digital, with revenue declining from $1.83B in 2012 to $890M in 2023. Noom's growth during this period (reaching $1B in revenue by 2023) suggests it has successfully captured market share from these legacy players. However, WW's acquisition of telehealth platform Sequence for $106M in 2023 signals its intent to compete more directly in the digital space and offer GLP-1 medications.

In the digital health arena, Noom faces competition from apps like MyFitnessPal and LoseIt!, which offer calorie tracking and basic health coaching. Noom distinguishes itself by combining these features with more intensive psychological support and human coaching.

The company's hybrid model of AI-assisted human coaches allows each coach to manage 300-400 users, compared to 7-15 for competitors like Vida Health and Omada. This scalability has been key to Noom's growth, though it has also led to mixed user sentiment regarding the quality of coaching support.

The rise of GLP-1 weight loss drugs like Ozempic and Wegovy has created a new competitive front. Companies like Ro and Calibrate have quickly moved to offer these medications through telehealth platforms. Noom has responded by launching Noom Med, its own GLP-1 prescription service.

Noom has differentiated with a dual-pronged GLP-1 strategy: offering lower-cost compounded microdoses and providing seamless access to branded drugs. The company's Microdose GLP-1Rx Program is priced at $99 to start (then $199/month), significantly undercutting the $349 price point for branded 2.5mg vials, with the company reporting that 70% of members receiving microdoses experienced no side effects.

Simultaneously, Noom has integrated with branded drug manufacturers, including an integration with LillyDirect's pharmacy provider Gifthealth to streamline access to FDA-approved Zepbound (tirzepatide) vials with in-app fill-status and shipping updates for members with on-label prescriptions. This positions Noom to capture value across different customer segments and regulatory environments—offering affordable compounded options while maintaining relationships with branded manufacturers as generic versions become available and compounding exceptions wind down.

This move allows Noom to potentially capture value from both the surging GLP-1 market and ongoing behavioral change support. However, it also increases commoditization risk as generic versions of these drugs become available.

Noom has tailwinds from the growing obesity epidemic and increasing consumer demand for digital health solutions, and has the opportunity to grow and expand into adjacent markets like chronic disease management, mental health, and enterprise wellness programs.

Noom's core weight loss app has proven product-market fit, growing from $12M in revenue in 2017 to over $600M in 2021. However, the company views weight loss as just the starting point for a broader behavior change platform. Noom is well-positioned to expand into other areas of health and wellness that require sustained lifestyle modifications.

A key adjacent market is chronic disease management. Noom has accelerated this expansion with the November 2025 launch of a Diabetes Lifestyle Program for employers and health plans. In a three-month pilot, nearly three-fourths of participants achieved a clinically significant A1C reduction, with an average A1C reduction of 1.0% and mean blood glucose reduction of 29 mg/dL.

Noom also introduced Glucose Forecasting in November 2025, which predicts the glucose impact of meals without requiring CGM hardware, available to enterprise and select consumer members. The company could further leverage its existing behavior change framework and technology to develop programs for conditions like hypertension, high cholesterol, and heart disease - all of which have strong links to obesity and lifestyle factors. With 60% of US adults having at least one chronic condition, this represents a massive potential market.

Noom has also begun expanding into longevity and preventive health. In December 2025, Noom launched Proactive Health Microdose GLP-1Rx at $149/month, combining microdosed GLP-1 with at-home biomarker testing every four months and a "Longevity Companion." In October 2025, Noom introduced AI-powered Face Scan in its free tier, which delivers a 30-second health screening with biological age estimate, vital signs (heart rate, breathing rate, stress levels), and metabolic/heart health indicators. This positions Noom to address preventive health concerns before they become chronic conditions.

Mental health is another promising expansion opportunity. Noom launched Noom Mood in 2021 to address stress and anxiety. This move aligns with growing awareness of the mind-body connection in health. Noom could further build out its mental health offerings to include programs for depression, sleep issues, and other common mental health concerns. The global mental health apps market is projected to reach $17.5B by 2030, indicating significant growth potential.

While Noom's growth to date has been primarily direct-to-consumer, the company has a major opportunity in the B2B market. Noom could offer its weight loss, chronic disease, and mental health programs to employers as part of corporate wellness initiatives. This would provide a new revenue stream and help Noom rapidly scale its user base.

Noom has accelerated its B2B expansion in 2025. In November 2025, the company launched a Diabetes Lifestyle Program specifically for employers and health plans. In December 2025, Noom partnered with Castlight Health to distribute Noom programs (Noom Weight, Noom Med, Noom Diabetes, Noom Diabetes Prevention) to employers and health plans via Castlight's platform, with Castlight claiming its platform can drive a 3.25x increase in engagement.

In July 2025, Noom committed to the CMS Digital Health Ecosystem Shared Framework at the White House and pledged to develop 30 days of free access to full Noom programs for Medicare and Medicaid members, potentially opening access to a massive government-insured population.

Noom has already begun pursuing pharmaceutical partnerships, including working with Novo Nordisk to offer its program alongside obesity medications and integrating with LillyDirect in March 2025 to streamline access to Zepbound for members with on-label prescriptions. Expanding these pharmaceutical partnerships, as well as developing relationships with insurers and large employers, could drive significant growth. The global corporate wellness market is expected to reach $94B by 2026.

In September 2025, Noom launched a free tier featuring "microhabits" programming, dramatically expanding its potential user base beyond paying subscribers.

In October 2025, Noom added AI-powered Face Scan and Future Me features to the free tier. Face Scan delivers a 30-second health screening with biological age, vital signs, and metabolic indicators, while Future Me visualizes how healthy vs. unhealthy habits could affect future appearance. This freemium strategy lowers barriers to entry and creates a larger funnel for converting users to paid subscriptions, particularly for its higher-priced GLP-1 medication programs.

By leveraging its core competencies in behavior change, mobile technology, and health coaching, Noom has the potential to become a comprehensive digital health platform addressing a wide range of wellness needs. This expansion strategy could grow Noom's total addressable market from the $70B weight loss industry to the broader $4T healthcare market.

1. Commoditization of weight loss advice: As AI and large language models become more sophisticated, they may be able to replicate much of Noom's personalized coaching and curriculum at a fraction of the cost. This could undermine Noom's value proposition and pricing power, especially as its coaching model already relies heavily on AI assistance. To mitigate this, Noom will need to continually innovate its behavioral change methodology and demonstrate superior outcomes.

2. Dependence on GLP-1 drugs: Noom's pivot to offering GLP-1 weight loss medications like Ozempic ties its fortunes closely to the availability and efficacy of these drugs. Supply shortages, new competing drugs, or unexpected side effects could severely impact Noom's growth. Additionally, as generic versions become available, Noom may struggle to maintain margins on drug sales. The company will need to diversify its offerings and demonstrate value beyond just drug access.

3. High customer acquisition costs: Noom has relied on massive advertising spend to fuel growth, with hundreds of millions spent annually on marketing. This creates pressure to monetize users quickly and could lead to churn if customers feel pressured into long-term commitments. Noom must find more efficient customer acquisition channels and focus on improving retention to justify its high CAC.